Compugen LTD Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NASDAQ

15 Feb 2025

CGEN

SCHEDULE 13G/A: Bristol-Myers Squibb Discloses 2.06% Passive Stake in Compugen Ltd.

Bristol-Myers Squibb Company has filed an amended Schedule 13G, reporting a 2.06% passive beneficial ownership stake in Compugen Ltd. as of December 31, 2024.